According to Healio, pimodivir significantly decreased viral load over seven days in adults with acute, uncomplicated seasonal influenza A.

The investigational drug is described in the news release as being a “first-in-class inhibitor of the PB2 subunit of the influenza A polymerase complex.” According to the release, it targets an alternative part of the viral replication process and may be used to treat influenza A virus infections that have developed resistance to existing antivirals with other modes of action.

Compared with placebo, treatment with pimodivir resulted in a statistically significant decrease in area under the curve (AUC) of viral load measured by qRT-PCR over 7 days from start of dosing at doses of 300 mg (–3.6 AUC; 95% CI, –7.1 to –0.1) and 600 mg (–4.5 AUC; 95% CI, –8.0 to –1.0).